Alessandro (Alex) Giambanco
About Alessandro (Alex) Giambanco
Alessandro (Alex) Giambanco is a Regional Sales Manager at Organogenesis, with a background in sales and management in the medical and pharmaceutical sectors. He has held various positions at ZOLL Medical Corporation and AstraZeneca, demonstrating a strong track record in sales performance and team leadership.
Current Role at Organogenesis
Alessandro Giambanco currently serves as the Regional Sales Manager at Organogenesis, a position he has held since 2021. He operates from Columbus, Ohio, where he leads a team of Tissue Regeneration Specialists. His focus is on advanced wound care and surgical sports medicine, specifically within the Columbus, Ohio, and West Virginia markets.
Previous Experience at ZOLL Medical Corporation
Prior to his current role, Giambanco worked at ZOLL Medical Corporation in various capacities. He was involved in the Advanced Sales Development Program for seven months in 2019 and served as a Senior Territory Manager for one year. He also participated in the Leadership Development Program and worked as a Field Sales Trainer, where he was recognized as a Subject Matter Expert.
Sales Experience at AstraZeneca and Pfizer
Giambanco's sales career includes experience at AstraZeneca, where he worked as a Primary Care Sales Specialist Overlay and a Diabetes Sales Specialist Overlay. His tenure at AstraZeneca spanned from 2013 to 2015. He also worked briefly as a Pharmaceutical Sales Representative at Pfizer in 2015.
Educational Background
Giambanco holds a Bachelor's degree in Business/Criminal Justice from Bluefield State College. He also earned an Associate's degree in Business Administration and Management from Potomac State College of West Virginia University. His educational background supports his extensive career in sales and management.
Achievements in Sales Performance
Throughout his career, Giambanco has achieved notable sales performance metrics. He was recognized as Regional MVP at Zoll Lifevest after achieving 118% to plan in 2016. He also demonstrated strong performance in 2020, achieving 116% to plan in Q2.